Bispecific ADCs

From Single Target to Multidimensional Breakthrough: The New Landscape and Strategic Evolution of Next-Generation ADC Drug Bioanalysis

by
From Single Target to Multidimensional Breakthrough: The New Landscape and Strategic Evolution of Next-Generation ADC Drug Bioanalysis

With the breakthrough progress of novel structures such as bispecific ADCs and dual payload ADCs, ADC drugs have transitioned from “single-target precision strikes” to a new era of “multidimensional collaborative operations.” These innovative designs greatly expand therapeutic potential but also make their molecular structures, mechanisms of action, and in vivo fates unprecedentedly complex. In this … Read more

Comparative Clinical Value of Bispecific ADC vs. Dual Payload ADC

by
Comparative Clinical Value of Bispecific ADC vs. Dual Payload ADC

The following article is sourced from Biotech Investment Notes, authored by Andy. As the technology of ADCs (Antibody-Drug Conjugates) evolves from the “first generation” to the “new generation”, bispecific ADCs and dual payload ADCs have emerged as two major research directions in the industry, breaking through the traditional single-target, single-payload ADCs. Although both are designed … Read more

Antibody-Drug Conjugates (ADCs): A Comprehensive Analysis from Basics to Frontiers

by
Antibody-Drug Conjugates (ADCs): A Comprehensive Analysis from Basics to Frontiers

Antibody-Drug Conjugates (ADCs) are precision anti-cancer drugs that combine the targeting ability of antibodies with potent cytotoxic agents, achieving precise strikes against tumor cells through a “biological missile” design. As of July 2025, a total of 19 ADC drugs have been approved globally, widely used in the treatment of various cancers such as breast cancer … Read more